Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Feb;75(2):486–495. doi: 10.1172/JCI111724

Studies of human C5a as a mediator of inflammation in normal human skin.

K B Yancey, C H Hammer, L Harvath, L Renfer, M M Frank, T J Lawley
PMCID: PMC423523  PMID: 2982914

Abstract

C5a is an 11,000-D fragment of the fifth component of complement (C5) with potent anaphylatoxic and leukocyte chemotactic activities. C5a is believed to play an important role in the pathophysiology of certain skin disorders and systemic diseases with cutaneous manifestations. However, there is very little known about the in vivo reactivity of C5a in man. In this study we examined the effects of intradermal injections of human C5a in 17 normal volunteers. C5a was prepared by interacting highly purified human C5 with zymosan bound alternative pathway C5 convertase under conditions resulting in consumption of approximately 90% of the C5 substrate. C5a produced in this manner was chemotactic for human neutrophils and monocytes (0.5 X 10(-7) to 10(-9) M) and caused neutrophil aggregation and myeloperoxidase release (concentrations greater than or equal to 10(-10) M) in vitro. In vivo, C5a produced immediate wheal and flare reactions in all volunteers, and was active in doses as low as 1 ng (10(-13) mol). Intradermal testing with 20 ng of C5a in eight volunteers produced a maximal mean wheal of 11.75 mm (+/- 0.80 mm SEM) 20 min after anaphylatoxin injection, and a maximal mean erythema of 62.50 mm (+/- 3.27 mm SEM) 10 min after C5a administration. Reactions at C5a test sites were dose-related, associated with marked pruritus in some subjects, resolved without lesion formation, and were not associated with late phase reactions. In vivo testing revealed that human C5a was a more potent mediator of wheal and flare reactions than histamine, 48/80, human C3a, or morphine sulfate. Skin biopsies from eight volunteers 20 min after intradermal injection of 20 ng of C5a revealed a neutrophil-predominant perivascular infiltrate, endothelial cell edema, and sites of leukocytoclasis. Mast cell degranulation was observed on both light and electron microscopy of biopsies from C5a test sites. Although erythema at C5a injection sites was reduced by pretreating volunteers with hydroxyzine, whealing reactions and cellular infiltrates in biopsies were unaffected by this H1-antihistamine. Moderate doses of systemic corticosteroids did not alter clinical or histologic reactions at C5a injection sites in two volunteers. This study, using doses within the potential physiologic range of the anaphylatoxin, provides a comprehensive assessment of the effect of human C5a on normal human skin.

Full text

PDF
486

Images in this article

488Image
on p.488
488Image
on p.488
488Image
on p.488
489Image
on p.489
491Image
on p.491
492Image
on p.492
493Image
on p.493

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Falk W., Goodwin R. H., Jr, Leonard E. J. A 48-well micro chemotaxis assembly for rapid and accurate measurement of leukocyte migration. J Immunol Methods. 1980;33(3):239–247. doi: 10.1016/0022-1759(80)90211-2. [DOI] [PubMed] [Google Scholar]
  2. Fernandez H. N., Henson P. M., Otani A., Hugli T. E. Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions. J Immunol. 1978 Jan;120(1):109–115. [PubMed] [Google Scholar]
  3. Goodman M. G., Chenoweth D. E., Weigle W. O. Potentiation of the primary humoral immune response in vitro by C5a anaphylatoxin. J Immunol. 1982 Jul;129(1):70–75. [PubMed] [Google Scholar]
  4. Gorski J. P., Hugli T. E., Müller-Eberhard H. J. C4a: the third anaphylatoxin of the human complement system. Proc Natl Acad Sci U S A. 1979 Oct;76(10):5299–5302. doi: 10.1073/pnas.76.10.5299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Grönneberg R., Strandberg K. Effect of terbutaline on cutaneous responses in man to rechallenge with allergen and compound 48/80. Allergy. 1981 Jan;36(1):33–38. doi: 10.1111/j.1398-9995.1981.tb01822.x. [DOI] [PubMed] [Google Scholar]
  6. Hall R. P., Lawley T. J., Smith H. R., Katz S. I. Bullous eruption of systemic lupus erythematosus. Dramatic response to dapsone therapy. Ann Intern Med. 1982 Aug;97(2):165–170. doi: 10.7326/0003-4819-97-2-165. [DOI] [PubMed] [Google Scholar]
  7. Hammer C. H., Wirtz G. H., Renfer L., Gresham H. D., Tack B. F. Large scale isolation of functionally active components of the human complement system. J Biol Chem. 1981 Apr 25;256(8):3995–4006. [PubMed] [Google Scholar]
  8. Hammerschmidt D. E., Bowers T. K., Lammi-Keefe C. J., Jacob H. S., Craddock P. R. Granulocyte aggregometry: a sensitive technique for the detection of C5a and complement activation. Blood. 1980 Jun;55(6):898–902. [PubMed] [Google Scholar]
  9. Hammerschmidt D. E., Weaver L. J., Hudson L. D., Craddock P. R., Jacob H. S. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value. Lancet. 1980 May 3;1(8175):947–949. doi: 10.1016/s0140-6736(80)91403-8. [DOI] [PubMed] [Google Scholar]
  10. Harvath L., Falk W., Leonard E. J. Rapid quantitation of neutrophil chemotaxis: use of a polyvinylpyrrolidone-free polycarbonate membrane in a multiwell assembly. J Immunol Methods. 1980;37(1):39–45. doi: 10.1016/0022-1759(80)90179-9. [DOI] [PubMed] [Google Scholar]
  11. Hugli T. E., Müller-Eberhard H. J. Anaphylatoxins: C3a and C5a. Adv Immunol. 1978;26:1–53. doi: 10.1016/s0065-2776(08)60228-x. [DOI] [PubMed] [Google Scholar]
  12. Hugli T. E. The structural basis for anaphylatoxin and chemotactic functions of C3a, C4a, and C5a. Crit Rev Immunol. 1981 Feb;1(4):321–366. [PubMed] [Google Scholar]
  13. José P. J., Forrest M. J., Williams T. J. Human C5a des Arg increases vascular permeability. J Immunol. 1981 Dec;127(6):2376–2380. [PubMed] [Google Scholar]
  14. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  15. Lawley T. J., Hall R. P. Circulating immune complexes in dermatologic disease. Springer Semin Immunopathol. 1981;4(3):221–240. doi: 10.1007/BF01892179. [DOI] [PubMed] [Google Scholar]
  16. Lim H. W., Novotny H., Gigli I. Role of complement and polymorphonuclear cells in demethylchlortetracycline-induced phototoxicity in guinea pigs. Inhibition by decomplementation in vivo. J Clin Invest. 1983 Oct;72(4):1326–1335. doi: 10.1172/JCI111088. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lim H. W., Perez H. D., Poh-Fitzpatrick M., Goldstein I. M., Gigli I. Generation of chemotactic activity in serum from patients with erythropoietic protoporphyria and porphyria cutanea tarda. N Engl J Med. 1981 Jan 22;304(4):212–216. doi: 10.1056/NEJM198101223040406. [DOI] [PubMed] [Google Scholar]
  18. Morgan E. L., Thoman M. L., Weigle W. O., Hugli T. E. Anaphylatoxin-mediated regulation of the immune response. II. C5a-mediated enhancement of human humoral and T cell-mediated immune responses. J Immunol. 1983 Mar;130(3):1257–1261. [PubMed] [Google Scholar]
  19. Soter N. A., Lewis R. A., Corey E. J., Austen K. F. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol. 1983 Feb;80(2):115–119. doi: 10.1111/1523-1747.ep12531738. [DOI] [PubMed] [Google Scholar]
  20. Vallota E. H., Müller-Eberhard H. J. Formation of C3a and C5a anaphylatoxins in whole human serum after inhibition of the anaphylatoxin inactivator. J Exp Med. 1973 May 1;137(5):1109–1123. doi: 10.1084/jem.137.5.1109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Webster R. O., Henson P. M. Rapid micromeasurement of neutrophil exocytosis. Inflammation. 1978 Jun;3(2):129–135. doi: 10.1007/BF00910734. [DOI] [PubMed] [Google Scholar]
  22. Webster R. O., Larsen G. L., Henson P. M. In vivo clearance and tissue distribution of C5a and C5a des arginine complement fragments in rabbits. J Clin Invest. 1982 Dec;70(6):1177–1183. doi: 10.1172/JCI110716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Wuepper K. D., Bokisch V. A., Müller-Eberhard H. J., Stoughton R. B. Cutaneous responses to human C 3 anaphylatoxin in man. Clin Exp Immunol. 1972 May;11(1):13–20. [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES